NASDAQ : DYN

Dyne Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 16.69 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.12B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Details

NameDyne Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees289
Founded1984
Ipo Date2020-09-17
CeoJohn Cox
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price19.00
IsinUS26818M1080
Cusip26818M108
Cik0001818794
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
John G. Cox M.B.A.Chief Executive Officer, President and Director
Erick J. Lucera C.F.A., CPAChief Financial Officer, Principal Financial Officer and Principal Accounting Officer and Treasurer
Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer
Johanna Friedl-NadererChief Commercial Officer
Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer
Dr. Axel WiestSenior Vice President and Head of Portfolio Strategy and Operations
Dr. Rajesh Manchanda Ph.D.Chief Technical Officer
James P. Bilotta M.B.A.Chief Digital and Information Officer
Alessandro MartuscelliChief Legal Officer
Lucia CelonaChief Human Resource Officer

Contact

Address1560 Trapelo Road, Waltham, Massachusetts 02451, United States
Phone781 786 8230
Websitehttps://www.dyne-tx.com